A/H is for rookies ... and games are, and will, be played! It's not always as it appears due to thin trades!
Have a beer/glass of wine and relax! Floyd delivered!!
Gee, thanks! I really appreciate the condescension and being lumped in the same boat as complacent Germans marching to Hitler's tune! I rest my case!
While I appreciate your attempt at sarcasm, my point is that your posts continuously attack people you don't agree with. How can that further any dialogue. Blanket statements like "the Republican party is morally bankrupt ... " is not only a very broad brush, once again, but very offensive. How can you possibly know the heart of ALL Republicans? I happen to be a former history teacher who believes our country has strayed so far from our Constitution and the ideas of our Founding Fathers that "extreme times may call for extreme measures". The pendulum has swung way too far from center ... yet, I would never presume to call you names! You do realize that our revolution was waged by a minority, don't you? There were approximately 30% loyal to the crown, 30% were "fence-sitters" and the rest were the active minority that moved to right the injustices being inflicted upon the taxpayers. Sound familiar?
Herd mentality ... selling begets selling, especially with a high short interest. Oil has been selling off, in general. Look at GDP today, down over 4%. Not necessarily HK specific. Now, after earnings, if it's not as expected, we'll know the herd was correct.
All the O/G stocks are being pressured today. Our moves are always more exaggerated ... and some heading for the exit ahead of earnings.
Keep your eyes on the prize ... buy the dips and take some off on the rips if you choose!
While coming into this "conversation" late ... might I suggest you not throw such a wide net for those who might not agree with you politically? It sounds as though you disapprove of "dirty old hydrocarbons", yet you will throw principle to the wind in order to profit from them? With that divergence, you leave little room for criticizing those on the other side for their beliefs. With all due respect, of course!! It's a little bit like Al Gore preaching to us about OUR carbon footprint all the while owning numerous homes, and flying around the country on private jets.
Also, golong ... CBST purchased TSRX early in the game. Why wouldn't someone else look at the likes of DRTX? THAT is not the reason I bought shares back ... mainly on a valuation basis.
Always appreciate your insight. I just re-entered because I still look at market cap as an indication of where the share price sits at the moment. I just feel that with the product approved, there is definitely some de-risking that should be factored in. I agree with you 100% on the "go it alone" strategy. Very difficult and hard to pull off. HUGE mistake for AMRN. Just wondering why you see it as "going up against" ... isn't there enough room in the antibiotic marketplace for new players? I know you have been in TTPH ... they're beaten down, as well ... are you more optimistic in that regard than DRTX? Just think there will be more partnerships going forward ... your thoughts?
Apparently, the market sees the 1H 2015 as a sign there's plenty of time to buy. However, this shows there is genuine worldwide interest in dalbavancin ... There are plenty of biotechs out there that are still in clinical trials and have a market cap higher than DRTX. I can wait!! And, as much as I HATE buyout speculation, at these levels it looks mighty tempting to big pharma, I'm sure. It would be a shame to settle for the % premium we got with TSRX, though!
Now, that I think about it, my memory failed. It must've been last fall ... my how time flies when you're having fun!
I see the thieves are not finished stealing shares!
This action reminds me of the time last spring when it kept going down for "no reason" and the powers that be took it under $8. It was a buying opportunity then, and I suspect it is now, as well.
For an approved drug? I'll buy at $13 all day long ... with new partnership (more to follow, most likely), downside risk is very limited, even given a potential secondary.
Take what the market gives you, folks!
Got lucky this a.m. at the open ... had a buy order in and it filled at $12.87. Too funny!
CHICAGO, July 30, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (DRTX) announced today that its Dutch subsidiary, Durata Therapeutics International B.V., has entered into a license and supply agreement with Angelini, an international group leader in the pharmaceutical and mass-market sectors, to commercialize dalbavancin in 36 countries, which include Italy, Spain, Poland, Portugal, many Eastern European countries, Russia, Turkey, and Commonwealth of Independent States.
Durata will receive an upfront payment from Angelini of $15 million and another $10 million upon European Medicines Agency (EMA) approval. The Company will also receive payments upon the achievement of certain countries' pricing approvals and sales milestones, as well as royalties on sales. Durata's Marketing Authorization Application (MAA) for dalbavancin is under review with the European Medicines Agency and anticipates a decision in 1H 2015.
Durata owns the worldwide rights for development and commercialization or partnering of dalbavancin. Durata is currently commercializing DALVANCE(TM) (dalbavancin) for injection in the U.S. and, if approved in the EU, may choose to directly commercialize in the remaining parts of Western Europe, including the United Kingdom, Germany, and France, with a targeted hospital salesforce and to use a variety of collaboration arrangements for commercialization in other markets.
"We are pleased to have entered into this agreement with Angelini, a well-respected pharmaceutical company with rich history and significant experience marketing hospital-based products. This partnership is aligned with our strategy to bring dalbavancin to the market for the millions of people who may benefit from an innovative treatment option for serious skin infections in today's evolving health care environment," said Paul R. Edick, Durata's Chief Executive Officer.
"Angelini is proud of partnering dalbavancin with Durata for treating patients affected by serious skin infections. The new approach will allow patients, healthcare professionals and hospitals to overcome the standard daily or twice-daily IV antibiotic infusions," said Gianluigi Frozzi, Angelini Pharmaceutical Division's Chief Executive Officer. "The agreement is part of the Angelini effort in the field of treatment of infectious diseases. Once approved in the EU, our experienced sales force and extensive network will bring dalbavancin to over 30 countries."
I was wondering where you've been all this time, so I checked to see your posting history. You sure are over-zealous in your enthusiasm for ACRX ... where were you before 7/23? Now, you virtually eat, sleep and breath ACRX? I smell a rat!!
golong, I totally agree. This is/will be a huge gift going forward. FDA approved ... no brainer! Only reason this has happened is speculation of the secondary and the low float. I'm gonna make some lemonade out of these lemons!!!